kff employer health benefits survey 2025 glp-1 coverage Survey: Key Trends and Insights for Public Sector KFF's survey of Medicaid officials

OBrien PD, Hinder LM, Callaghan BC, Feldman EL (2017) Neurological consequences of obesity

Featured image: NADMED technology comes in kits that require only basic laboratory equipment

Notice: For adults only and does not replace a varied balanced diet and healthy lifestyle

Every one of our formulations is third-party tested for purity

Starting a new medication like Mounjaro (tirzepatide) can take some getting used to, especially if you find yourself experiencing side effects like nausea

GLP-1RAs, which are approved to treat type 2 diabetes, obesity, and obstructive sleep apnea, are now being investigated for their effects on processes involving appetite and satiety, reward processing, stress regulation, cognition, and neuroinflammation